Oucome of Board Meeting held today, Wednesday, November 12, 2025 along with financial results, LRR report & Certificate of IPO Proceeds
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Clinitech Laboratory's board approved unaudited financial results for H1 FY26 (half year ended September 30, 2025) along with the Limited Review Report and IPO proceeds utilization certificate. Revenue from operations stood at ₹415.89 lakhs, down from ₹508.02 lakhs in the same period last year. Profit after tax fell to ₹17.37 lakhs versus ₹30.03 lakhs in H1 FY25, with EPS dropping sharply to ₹0.17 from ₹0.83. The board also approved the formation of a new subsidiary, though no further details were disclosed. As per the IPO proceeds certificate, the company has raised ₹578.30 lakhs and utilized ₹428.30 lakhs so far, with ₹150 lakhs still pending deployment mainly toward expansion of the diagnostic business.
Weak H1 results with declining revenue and profits, combined with significant unutilized IPO funds, may concern shareholders. The new subsidiary formation could signal future expansion or diversification plans, which may be worth watching.